Share

February 12, 2019; 92 (7) Editorial

Psychogenic nonepileptic seizures, conversion, and somatic symptom disorders

Selim R. Benbadis
First published January 4, 2019, DOI: https://doi.org/10.1212/WNL.0000000000006838
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
339

Share

Article Information

vol. 92 no. 7 311-312
DOI: 
https://doi.org/10.1212/WNL.0000000000006838
PubMed: 
30610096
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published January 4, 2019.

Article Versions

Copyright & Usage: 
© 2019 American Academy of Neurology

Author Disclosures

    1. Selim R. Benbadis, MD
  1. Selim R. Benbadis, MD
    2. Scientific Advisory Boards:

    1. Advisory Board for Cyberonics/LivaNova, Eisai, Greenwich, Lundbeck, Neuropace, Sunovion.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Editorial Board: Emedicine-Medscape-WebMD, European Neurology, Epileptic Disorders, Epilepsy and Behavior, Expert Review of Neurotherapeutics.

    Patents:

    1. NONE

    Publishing Royalties:

    1. 1. UpToDate. 2. Medscape/WebMD.

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Cyberonics/LivaNova, Eisai, Greenwich, Lundbeck, Neuropace, Sunovion.

    Speakers' Bureaus:

    1. Speakers Bureau: Cyberonics/LivaNova, Eisai, Greenwich, Lundbeck, Neuropace, Sunovion.

    Other Activities:

    1. NONE

    Clinical procedures or imaging studies:

    1. The University of South Florida (Tampa General Hospital) Epilepsy Center is a level-4 center, and as such performs all available treatment: medications, neurostimulation, and surgery.

    Research Support, Commercial Entities:

    1. Clinical trials: Cavion, LivaNova, GW, Sunovion, UCB.

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the University of South Florida, Tampa.
  1. Correspondence
    Dr. Benbadis sbenbadi{at}health.usf.edu
View Full Text

Article usage

Article usage: January 2019 to April 2022

AbstractFullPdfSource
Jan 2019502080Highwire
Feb 201954612675Highwire
Mar 20191672525Highwire
Apr 2019108816Highwire
May 20199237Highwire
Jun 20198067Highwire
Jul 20198768Highwire
Aug 201949108Highwire
Sep 20194925Highwire
Oct 20194923Highwire
Nov 20195556Highwire
Dec 20193855Highwire
Jan 20206102Highwire
Feb 20205757Highwire
Mar 202083710Highwire
Apr 20205248Highwire
May 20205126Highwire
Jun 202053212Highwire
Jul 20203723Highwire
Aug 20202133Highwire
Sep 20203638Highwire
Oct 20206310Highwire
Nov 20205411Highwire
Dec 20208935Highwire
Jan 20212913Highwire
Feb 20214611Highwire
Mar 20216237Highwire
Apr 20213311Highwire
May 20213201Highwire
Jun 20214854Highwire
Jul 20213412Highwire
Aug 20214622Highwire
Sep 20213221Highwire
Oct 20213920Highwire
Nov 20214521Highwire
Dec 20213700Highwire
Jan 20223011Highwire
Feb 20225012Highwire
Mar 202210511Highwire
Apr 20225642Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me